ClinicalTrials.gg
Not yet recruitingNCT07811453GTO-001Updated Sep 10, 2026

Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options

An interventional study of Liver transplantation in Colorectal Neoplasms, Liver Neoplasms and Neoplasm Metastases, sponsored by Charite University, Berlin, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Colorectal Neoplasms by Charite University, Berlin, Germany — 3 open to participants now, 3 under way, 1 of them phase 3. Colorectal Neoplasms · Charite University, Berlin, Germany.

Started
2027
the only one that year
No phase
4 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Colorectal Neoplasms by Charite University, Berlin, Germany, this one is the only one that started in 2027, is one of 4 with no phase, and was the 10th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 10 studies in Colorectal Neoplasms by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colorectal Neoplasms by Charite University, Berlin, Germany, or all of them as a file.
02

Study summary

Patients whose colorectal cancer has spread to the liver, and whose liver metastases cannot be removed by surgery or destroyed by ablation, currently receive palliative chemotherapy in Germany. Fewer than one in ten of these patients survive five years. International studies have shown that replacing the whole liver by transplantation can achieve much longer survival in carefully selected patients, because removing the entire liver removes all of the tumour when the disease is confined to it. The TransMet trial reported five-year survival of 57% with transplantation plus chemotherapy, compared with 13% for chemotherapy alone. This approach is not yet available in German routine care, where liver transplantation for this indication is permitted only within a clinical study.

GTO-001 will enrol approximately 260 adults aged 18 to 65 years with colorectal liver metastases that are confined to the liver, that cannot be removed or ablated, and that have remained stable or improved for at least six months on chemotherapy. Every participant is assessed by a newly established National Tumor Board for Transplant Oncology, which meets monthly, reviews the imaging and case independently of the local centre, and decides whether the patient may be listed for transplantation. Patients who are approved are listed with a study-specific priority status, continue their chemotherapy while they wait, and undergo a surgical inspection of the abdomen at the start of the transplant operation to confirm that the cancer has not spread outside the liver. Participants who are not listed, or in whom transplantation is not performed, remain in the study and are followed in the same way.

The main question is how many patients are alive five years after transplantation. The study also measures how many of the patients assessed are eventually listed and transplanted, how many leave the waiting list because their disease progresses or becomes operable, survival after each of the treatments patients actually receive, how well the transplanted livers function, and complications after surgery. Because the study follows everyone who is assessed, it will also establish for the first time how many patients in Germany genuinely qualify for this treatment. Participants are followed for five years after transplantation; the study runs until 2036.

Read the detailed description

Rationale. Colorectal liver metastases (CRLM) are resectable in only 20-40% of patients. For the remainder, palliative systemic therapy is the only option recommended by the German S3 and ESMO guidelines, with 5-year overall survival of approximately 10%. The premise of transplant oncology is that total hepatectomy constitutes an R0 resection provided disease is liver-confined. The Oslo experience (61 transplanted patients, median overall survival 60.3 months, 5-year survival 50.4%) and the randomised TransMet trial (5-year overall survival 57% vs 13% intention-to-treat; 73% vs 9% per protocol) support the approach, but neither has been reproduced under Eurotransplant allocation. In Germany, patients with non-resectable CRLM are not eligible for a ReMELD-Na Standard Exception, and under Section 16(1)(1) nos. 2 and 5 of the German Transplantation Act, liver transplantation for oncological indications beyond established ones is permissible only within clinical studies.

Design and selection. GTO-001 is a prospective, multicentre, non-randomised, non-blinded interventional study at up to 19 German transplant centres, coordinated by Charité - Universitätsmedizin Berlin. Randomisation to a non-transplant arm was judged neither ethically justifiable nor feasible given the magnitude of the survival difference already demonstrated. Bias is instead addressed by strict eligibility criteria, binding central adjudication of resectability and listing, centralised imaging assessment on pseudonymised data transferred through the RACOON network, uniform standard operating procedures across sites, structured investigator training, and independent DSMB oversight.

Two selection features distinguish GTO-001 from TransMet: a mandatory period of at least six months of disease control under active chemotherapy before listing (TransMet required three), and prospective application of a PET-derived metabolic tumour volume threshold of 70 cm³, a cut-off associated with recurrence-free and overall survival in the Norwegian SECA experience and subsequently validated in a two-centre transplanted cohort. BRAF V600E mutation and MSI-H/dMMR status of the colorectal primary are exclusion criteria.

Conduct. Approved patients are listed through their local transplant conference and receive a study-specific ReMELD-Na Standard Exception on application to Eurotransplant. Systemic chemotherapy continues until transplantation, without anti-EGFR antibodies, anti-VEGF antibodies or checkpoint inhibitors. Surveillance during waiting comprises CT of chest, abdomen and pelvis and CEA every three months. Patients are removed from the list if progression is suspected, and relisted once disease control is re-established. Grafts are allocated by Eurotransplant; living donation is an equally acceptable option to be evaluated per patient; full and split grafts are both permitted, but staged hepatectomy techniques are not. All patients undergo a mandatory staging exploration - as the first step of deceased-donor transplantation, or within seven days before living-donor transplantation - performed by a surgeon with more than 50 liver resections or transplants, comprising systematic four-quadrant inspection of the peritoneal cavity with frozen-section examination of suspicious findings before hepatectomy begins. Transplantation is abandoned and the graft reallocated without delay if CEA exceeds 80 ng/mL preoperatively, or if peritoneal or extrahepatic disease is found. Follow-up after transplantation is every 4 weeks to month 3, every 3 months to year 3, then every 6 months to year 5, each visit comprising clinical examination, laboratory testing with tumour markers, and CT of chest, abdomen and pelvis.

Sample size. Approximately 260 patients will be screened and enrolled. Based on the Toronto experience, about 50% of patients proposed by local boards are expected to pass central review and about 80% of listed patients to drop out before transplantation, so approximately 26 patients (10% of those enrolled) are expected to undergo transplantation. The primary statistical objective is to demonstrate that 5-year survival after transplantation exceeds 50%, equivalent to median survival beyond 5 years. Assuming 65% 5-year survival and constant hazards, median survival is 8.041 years; with 9 expected deaths the one-sided 95% confidence interval for median survival is (5.014, ∞), which supports the conclusion, whereas 8 expected deaths would give (4.893, ∞) and would not. Nine expected events therefore require 26 transplanted patients. Alpha is 5% and no interim analysis is planned.

Analysis populations. The transplant cohort (patients transplanted after board approval and without contraindications at transplantation) is used for the primary analysis. The screened cohort comprises all patients screened, retaining those who withdraw or become ineligible through progression. The as-treated cohort comprises screened patients who received one of the three definitive treatments - transplantation, local treatment, or systemic treatment alone. The primary endpoint is estimated by Kaplan-Meier with a two-sided 95% confidence interval. As-treated comparisons use log-rank tests and Cox proportional hazards models adjusted for age and sex. Missing data are handled by multiple imputation using chained equations under a missing-at-random assumption, with 20 imputed datasets combined by Rubin's rules. A statistical analysis plan will be finalised before database lock.

Governance. The study is conducted in accordance with ICH E6 (R3), the Declaration of Helsinki, and the Professional Code for Physicians of the competent State Chamber of Physicians. Data are captured pseudonymously in a server-based eCRF (secuTrial); Charité is the controller under Art. 4 no. 7 GDPR, with consent as the legal basis under Art. 6(1)(a) and Art. 9(2)(a) GDPR. Monitoring is performed by the Charité Clinical Trial Office on a risk-adapted basis. An optional translational sub-study biobanks blood from all enrolled participants and a liver wedge biopsy from transplanted participants at the Charité central biobank (ZeBanC).

03

Conditions studied

  • Colorectal Neoplasms
  • Liver Neoplasms
  • Neoplasm Metastases
  • Colorectal Liver Metastases
  • Metastatic Colorectal Cancer (CRC)

Keywords

  • liver transplantation
  • transplant oncology
  • colorectal liver metastases
  • unresectable
  • metabolic tumor volume
  • PET/CT
  • organ allocation
  • Eurotransplant
  • central tumour board
  • circulating tumour DNA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years at enrolment
  • performance status 0 or 1
  • Written before any study-related procedure
  • Colorectal liver stable for at least 6 months under active chemotherapy of no more than 2 lines
  • Colorectal liver metastases not amenable to curative local treatment by resection or ablation because of insufficient liver capacity or future liver remnant, as judged by the local interdisciplinary tumour board
  • For metachronous colorectal liver metastases: a colorectal primary resected in the past with T4a or lower and local R0 status
  • For synchronous colorectal liver metastases: a potentially curatively resectable primary
  • No evidence of peritoneal disease, as documented by a surgical report within the preceding 36 months
  • Suitability for liver transplantation according to local centre criteria
  • Participants of : negative highly sensitive pregnancy test before inclusion, and use of a method with a failure rate below 1%, or confirmed status

Exclusion criteria

Exclusion Criteria:

  • Inability to give
  • General to liver transplantation
  • Large-vessel infiltration
  • Extrahepatic disease, including lymph node involvement
  • Listing for multi-organ transplantation
  • Prior solid organ or bone marrow transplantation
  • BRAF V600E mutation in the molecular pathology of the colorectal primary
  • MSI-H/dMMR status in the molecular pathology of the colorectal primary
  • Breastfeeding
  • Institutionalisation by order of a court or public authority
  • Dependence on the overall study lead, the investigator or the study site
  • Participation in another clinical study with an medicinal product or medical device
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Liver transplantation pathway

    Participants with liver-confined, non-resectable colorectal liver metastases stable for at least six months on active chemotherapy are assessed centrally by the National Tumor Board for Transplant Oncology. Those approved are listed for liver transplantation with a study-specific ReMELD-Na Standard Exception, continue systemic chemotherapy until transplantation, undergo mandatory staging exploration, and receive liver transplantation. Participants not approved or not transplanted remain enrolled and are followed identically.

    Procedure: Liver transplantation

Interventions

  • ProcedureLiver transplantation

    Orthotopic liver transplantation with a full or split graft from a deceased donor allocated by Eurotransplant under a study-specific ReMELD-Na Standard Exception, or from a living donor where evaluated as suitable by the participating centre. Staged hepatectomy techniques are not permitted. Machine perfusion may be used for graft assessment and preservation in accordance with the German guidelines for organ transplantation. Systemic chemotherapy continues until transplantation, excluding anti-EGFR antibodies, anti-VEGF antibodies and checkpoint inhibitors. Immunosuppression and perioperative care follow local site protocols; post-transplant chemotherapy is resumed at the discretion of the local tumour board and is not a study-specific intervention. Re-transplantation may be requested from Eurotransplant for primary non-function or surgical complications where the recipient meets the criteria of the German guidelines.

06

What researchers measure

Primary outcomes

  1. Overall survival at 5 years after liver transplantation

    Proportion of transplanted participants alive 5 years after liver transplantation, estimated by the Kaplan-Meier method with a two-sided 95% confidence interval, in the transplant cohort (participants transplanted after approval by the National Tumor Board and without study-specific contraindications at the time of transplantation). Time origin is the date of transplantation; the event is death from any cause; participants with missing survival information from a given visit onwards are censored at the last completed follow-up visit. Higher values indicate better outcome. The study is designed to demonstrate 5-year survival above 50%, equivalent to median survival exceeding 5 years.

    Time frame: 60 months after liver transplantation

Secondary outcomes

  1. Proportion of enrolled participants listed for liver transplantation

    Number of participants approved and listed for liver transplantation by the National Tumor Board, divided by the number of participants enrolled and screened, reported for the screened cohort as a proportion with a 95% confidence interval.

    Time frame: From enrolment to end of recruitment (36 months)

  2. Proportion of listed participants who undergo liver transplantation

    Number of participants transplanted divided by the number listed, reported for the screened cohort as a proportion with a 95% confidence interval.

    Time frame: From listing to end of study (up to 108 months)

  3. Waiting-list dropout after listing

    Number and proportion of listed participants removed from the waiting list without transplantation, reported with the reason for removal (disease progression, secondary resectability, death, or other), for the screened cohort.

    Time frame: From listing to end of study (up to 108 months)

  4. Overall survival from enrolment

    Proportion of participants alive at each timepoint, estimated by Kaplan-Meier on the time-since-inclusion scale in the screened cohort, irrespective of the treatment ultimately received. Higher values indicate better outcome.

    Time frame: 12, 36 and 60 months after enrolment

  5. Progression-free survival from enrolment

    Proportion of participants alive without disease progression, estimated by Kaplan-Meier on the time-since-inclusion scale in the screened cohort. Progression is assessed on CT of chest, abdomen and pelvis using RECIST. Higher values indicate better outcome.

    Time frame: 12, 36 and 60 months after enrolment

  6. Overall, progression-free, disease-free and recurrence-free survival by treatment received

    Each of overall, progression-free, disease-free and recurrence-free survival, estimated by Kaplan-Meier on the time-since-treatment-start scale in the as-treated cohort, separately for the three definitive treatments received - liver transplantation, local treatment (resection or ablation), and systemic therapy alone - and compared between groups by log-rank test. Univariable and multivariable Cox proportional hazards models with treatment group as covariate and adjustment for age and sex are reported as hazard ratios with 95% confidence intervals. Higher survival proportions indicate better outcome.

    Time frame: 12, 36 and 60 months after start of the definitive treatment received

  7. Graft survival after liver transplantation

    Proportion of transplanted participants with a functioning primary graft, estimated by Kaplan-Meier in the transplant cohort. The event is graft loss, defined as re-transplantation or death with a non-functioning graft. Higher values indicate better outcome.

    Time frame: 12, 36 and 60 months after liver transplantation

  8. Postoperative morbidity after liver transplantation (Comprehensive Complication Index)

    Postoperative morbidity in the transplant cohort, summarised descriptively using the Comprehensive Complication Index, which aggregates all complications of a patient weighted by Clavien-Dindo severity on a scale from 0 (no complication) to 100 (death). Lower values indicate better outcome.

    Time frame: Up to 3 months after liver transplantation

  9. Proportion of enrolled participants receiving local treatment

    Number and proportion of enrolled participants who undergo local treatment by resection or ablation, including those whose metastases became resectable during the period of disease control, reported descriptively for the screened cohort.

    Time frame: From enrolment to end of study (up to 108 months)

  10. Graft survival at 3 months after liver transplantation (safety endpoint)

    Proportion of transplanted participants with a functioning primary graft 3 months after transplantation, estimated in the transplant cohort. Prespecified safety endpoint. Higher values indicate better outcome.

    Time frame: 3 months after liver transplantation

  11. Patient survival at 1 year after liver transplantation (safety endpoint)

    Proportion of transplanted participants alive 1 year after transplantation, estimated in the transplant cohort. Prespecified safety endpoint. Higher values indicate better outcome.

    Time frame: 12 months after liver transplantation

Other outcomes

  1. Association of the Oslo score with 5-year survival after liver transplantation

    Association between the pre-transplant Oslo score and 5-year overall survival in the transplant cohort, assessed by univariable Cox proportional hazards regression and reported as a hazard ratio with a 95% confidence interval. Exploratory; no multivariable modelling is performed given the small number of expected events.

    Time frame: 60 months after liver transplantation

  2. Association of the Fong Clinical Risk Score with 5-year survival after liver transplantation

    Association between the pre-transplant Fong Clinical Risk Score and 5-year overall survival in the transplant cohort, assessed by univariable Cox proportional hazards regression and reported as a hazard ratio with a 95% confidence interval. Exploratory.

    Time frame: 60 months after liver transplantation

  3. Association of circulating tumour DNA with 5-year survival after liver transplantation

    Association between pre-transplant circulating tumour DNA and 5-year overall survival in the transplant cohort, assessed by univariable Cox proportional hazards regression and reported as a hazard ratio with a 95% confidence interval. Exploratory.

    Time frame: 60 months after liver transplantation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data will not be shared due to data protection regulations and ethical considerations. Given the sensitive nature of the data, strict confidentiality measures must be maintained to protect participants' privacy. Compliance with GDPR and institutional policies prevents the disclosure of personally identifiable information, ensuring that data handling aligns with legal and ethical standards

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Mar 2036, 107 months later.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 107 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 10, 2026
StartEst.
Apr 1, 2027
Primary completionEst.
Mar 31, 2036
CompletionEst.
Mar 31, 2036
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07811453
Collaborators
LMU Klinikum, German Cancer Aid, University Hospital Muenster
Responsible party
Nathanael Raschzok (Overall Study lead, Charite University, Berlin, Germany) — Principal investigator
First posted
Sep 10, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Mar 31, 2036 (estimated)
Completion
Mar 31, 2036 (estimated)
Last update
Sep 10, 2026

Study contacts

Nathanael Raschzok, Prof. Dr.
Contact
nathanael.raschzok@charite.de
+49 30 450 552 001
Simon Moosburner, Priv.-Doz. Dr.
Contact
simon.moosburner@charite.de

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion